Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Merck
Moodys
McKinsey
AstraZeneca

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR KAPVAY


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Kapvay

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00588354 ↗ Epidural Clonidine for Lumbosacral Radiculopathy Terminated National Center for Research Resources (NCRR) N/A 2006-10-01 This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00588354 ↗ Epidural Clonidine for Lumbosacral Radiculopathy Terminated Mayo Clinic N/A 2006-10-01 This was a randomized, blinded study of transforaminal epidural injection of clonidine versus a similar injection of corticosteroid for acute lumbosacral radiculopathy. The hypothesis was that clonidine will be as effective as steroid for this condition.
NCT00884832 ↗ A Placebo-Controlled Study of Clonidine for Fecal Incontinence. Completed National Center for Research Resources (NCRR) Phase 2 2008-10-01 Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women.
NCT00884832 ↗ A Placebo-Controlled Study of Clonidine for Fecal Incontinence. Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2008-10-01 Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women.
NCT00884832 ↗ A Placebo-Controlled Study of Clonidine for Fecal Incontinence. Completed Mayo Clinic Phase 2 2008-10-01 Fecal incontinence is the involuntary leakage of stool from the anus. Doctors at Mayo Clinic are doing a research study to assess the effects of a medication, clonidine, on fecal incontinence and rectal functions in women. Clonidine has been approved by the Food and Drug Administration (FDA) for treating high blood pressure, but not for treating incontinence and rectal functions. The hypothesis of this study is clonidine will improve fecal incontinence, increase rectal capacity and reduce rectal sensation to a greater extent than placebo in women.
NCT01439126 ↗ Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder Completed Concordia Pharmaceuticals Inc., Barbados Phase 4 2011-08-01 The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Kapvay

Condition Name

Condition Name for Kapvay
Intervention Trials
Attention Deficit Hyperactivity Disorder 1
Fecal Incontinence 1
Lumbar and Other Intervertebral Disc Disorders With Radiculopathy 1
Opiate Addiction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Kapvay
Intervention Trials
Radiculopathy 1
Intervertebral Disc Displacement 1
Pain, Postoperative 1
Intervertebral Disc Degeneration 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kapvay

Trials by Country

Trials by Country for Kapvay
Location Trials
United States 3
Lithuania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Kapvay
Location Trials
Minnesota 2
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kapvay

Clinical Trial Phase

Clinical Trial Phase for Kapvay
Clinical Trial Phase Trials
Phase 4 2
Phase 2 1
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Kapvay
Clinical Trial Phase Trials
Completed 3
Terminated 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kapvay

Sponsor Name

Sponsor Name for Kapvay
Sponsor Trials
National Center for Research Resources (NCRR) 2
Mayo Clinic 2
Arthroplasty Foundation, Inc. 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Kapvay
Sponsor Trials
Other 7
NIH 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
McKesson
Moodys
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.